NTRK1 and thyroid gland carcinoma: To further determine the oncogenic activity of EHF in thyroid cancer cells through activating HER2/HER3, we used a selective HER2 receptor tyrosine kinase inhibitor CP-724714 to suppress HER2 activation in the indicated cells.